Actively Recruiting
Study of Doravirine and DoravirineLamivudineTenofovir Disoproxil Fumarate in Children With HIV-1 Aged 4 Weeks to Less Than 12 Years and Under 45 kg
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-27
84
Participants Needed
26
Research Sites
282 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying pediatric participants aged 4 weeks to less than 12 years with human immunodeficiency virus type 1 HIV-1 infection, weighing under 45 kg. The study focuses on treatment-naive children or those virologically suppressed on stable combination antiretroviral therapy for at least 3 months without treatment failure. The main goals are to evaluate the steady-state pharmacokinetics, safety, and tolerability of doravirine DOR when given with two nucleosidenucleotide reverse transcriptase inhibitors NRTIs or as part of the fixed-dose combination FDC of DORlamivudinetenofovir disoproxil fumarate DOR3TCTDF in children aged 6 to less than 12 years weighing 14 to less than 45 kg. Participants receive oral doravirine doses ranging from 7.2 mg to 100 mg based on weight, combined with two NRTIs according to local guidelines, or the fixed-dose combination DOR3TCTDF, for a treatment period of 96 weeks. Those completing the Week 96 visit may join an extension study to receive doravirine for up to an additional 224 weeks or until commercial availability. The study is open-label and conducted across multiple sites. During the study, participants undergo intensive pharmacokinetic sampling at designated times up to 24 hours postdose to measure doravirine levels in plasma. Researchers also monitor safety outcomes up to 24 weeks and additional secondary outcomes including viral load, CD4 T-cell counts, adverse events, adherence, and palatability of the oral pellets or granules. Assessments continue through Week 96, with close monitoring of viral suppression, drug resistance, and tolerability throughout the study and extension period.
CONDITIONS
Brief Title
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here